-
Dasatinib, sold
under the
brand name
Sprycel among others, is a
targeted therapy medication used to
treat certain cases of
chronic myelogenous leukemia...
- to TK inhibitors, four
novel agents were
later developed. The first,
dasatinib,
blocks several further oncogenic proteins, in
addition to more potent...
-
except for T315I.
Dasatinib is also not a
substrate of
multidrug P-glycoprotein
efflux pumps like imatinib.
Because of this
dasatinib may be
active in...
- sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib,
dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib...
- are
repurposed anti-cancer molecules, such as the
chemotherapeutic drug
dasatinib and the
experimental small molecule navitoclax.
Soluble urokinase plasminogen...
- are point-mutations in the
kinase of BCR-abl. New
inhibitors include dasatinib and nilotinib,
which are
significantly more
potent than
imatinib and may...
- kinases) have been
developed for
therapeutic use. One
notable example is
dasatinib which has been
approved for the
treatment of
chronic myeloid leukemia...
- Agonists:
Ancestim Stem cell
factor Kinase inhibitors:
Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib...
- alefacept, and the
tyrosine kinase inhibitors, imatinib, nilotinib, and
dasatinib.
Experimental therapies under investigation include endothelin receptor...
- D+Q may
refer to:
Dasatinib#
Dasatinib+Quercetin
Drawn &
Quarterly This
disambiguation page
lists articles ****ociated with the
title D+Q. If an internal...
